Drug General Information |
Drug ID |
D02ANE
|
Former ID |
DNC013923
|
Drug Name |
1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C15H15N
|
Canonical SMILES |
C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3
|
InChI |
1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2
|
InChIKey |
HKHCSWPSUSWGLI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Serotonergic synapsehsa04728:Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
5HT1 type receptor mediated signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
5HT3 type receptor mediated signaling pathway
|
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
Parkinson disease
|
Dopamine receptor mediated signaling pathway
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
Reactome
|
Na+/Cl- dependent neurotransmitter transporters
|
WikiPathways
|
Monoamine Transport
|
SIDS Susceptibility Pathways
|
NRF2 pathway
|
Synaptic Vesicle Pathway
|
Serotonin Transporter ActivityWP727:Monoamine Transport
|
Dopaminergic Neurogenesis
|
Parkinsons Disease Pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
Neurotransmitter Clearance In The Synaptic Cleft
|
References |
REF 1 | Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. Epub 2008 May 23.Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. |